US20130012712A1 - Method for preparing disubstituted piperidine and intermediates - Google Patents

Method for preparing disubstituted piperidine and intermediates Download PDF

Info

Publication number
US20130012712A1
US20130012712A1 US13/616,995 US201213616995A US2013012712A1 US 20130012712 A1 US20130012712 A1 US 20130012712A1 US 201213616995 A US201213616995 A US 201213616995A US 2013012712 A1 US2013012712 A1 US 2013012712A1
Authority
US
United States
Prior art keywords
formula
compound
action
acid
order
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/616,995
Inventor
Alain Priour
Alain Bonnet
Gilles Oddon
Alain Mazurie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forest Laboratories Holdings ULC
Original Assignee
Forest Laboratories Holdings ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Laboratories Holdings ULC filed Critical Forest Laboratories Holdings ULC
Priority to US13/616,995 priority Critical patent/US20130012712A1/en
Publication of US20130012712A1 publication Critical patent/US20130012712A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/38—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention relates to a method for preparing a 2,5-disubstituted pyridine and novel intermediates.
  • P 1 and P 2 represent protecting groups of carboxylic acid and oxyamine functions, known to those skilled in the art, and notably those mentioned in PCT Application WO 02/10172.
  • the compound of formula (I) is in the form of a mixture of isomers (2S, 5R) and (2S, 5S).
  • the compound of formula (I) may be obtained as described in PCT Application WO 02/10172, notably in Example 32, starting from protected cis-5-hydroxy-piperidine-2-carboxylic acid.
  • the object of the present invention is a novel method for preparing the compound of formula (I), characterized in that the compound of formula (b):
  • P 1 and P 3 are defined as here above and P 2 represents a protecting group of the oxime, the amine of which is deprotected by the action of an acid, in order to obtain the compound of formula:
  • the beta-ketosulfoxonium compound of formula (b) may be obtained starting with the protected (S) pyrroglutamic acid of formula (a):
  • the protecting group of the carboxylic acid function P 1 is notably an alkyl, allyl, benzyl or p-nitrobenzyl ester residue; equivalent residues known to those skilled in the art may of course also be suitable.
  • P 1 preferably is a benzyl group.
  • the protecting group of the nitrogen P 3 notably forms a carbamate and preferably is a tert-butoxycarbonyl or benzyloxycarbonyl group, it may also be an electro-withdrawing group such as those known to one skilled in the art and referenced in ⁇ Greene>> (Protective Groups in Organic Synthesis, 3 rd edition).
  • P 3 preferably is a tert-butoxycarbonyl group.
  • the protecting group of the hydroxylamine P 2 is notably a benzyl or ally residue.
  • P 2 preferably is a benzyl group.
  • the conditions generating HCl and allowing preparation of the compound of formula (II) preferably consist of using lithium chloride in the presence of a strong acid.
  • Hydrochloric acid may also simply be used.
  • the strong acid is for example hydrochloric acid, sulfuric acid, sulfonic acid such as methane sulfonic acid or ethane sulfonic acid.
  • lithium chloride is used in the presence of methane sulfonic acid.
  • an ether such as tetrahydrofurane or dioxane
  • dimethylsulfoxide or within an ester such as ethyl acetate.
  • Deprotection of the amine function is achieved by the action of an acid, for example hydrochloric acid, sulfonic acid, trifluoroacetic acid or an alkane sulfonic acid.
  • an acid for example hydrochloric acid, sulfonic acid, trifluoroacetic acid or an alkane sulfonic acid.
  • these conditions are known to one skilled in the art.
  • Advantageous conditions consist of using a tert-butoxycarbonyl group and of cleaving it by the action of methane sulfonic acid. This may be performed for example in ethyl acetate.
  • the protected ⁇ -chlorooxime of formula (III) is preferably used without being isolated, i.e. in solution in the reaction solvent. The same applies for the protected ⁇ -chlorooxime of formula (IV).
  • the base used for cyclizing the compound of formula (IV) is for example an alkaline hydroxide, carbonate or bicarbonate, preferably sodium bicarbonate, or a base of the amine type, for example triethylamine.
  • the reducing agent used for reducing the oxime function is for example a reagent of the alkaline borohydride, diborane or borane-pyridine type in the presence of an acid, for example hydrochloric acid. This may be performed within an alcohol such as methanol or ethanol, or within another organic solvent such as dichloromethane.
  • the salification of the compound of formula (I) is, if necessary, achieved by adding to the compound an acid in a soluble phase.
  • salts of the acids used for obtaining the products of formula (I) mention may be made, inter alia, to those formed with inorganic acids, such as hydrochloric, hydrobromic, hydroiodic, sulfuric or phosphoric acids, or with organic acids such as formic, acetic, trifluoroacetic, propionic, benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic, glyoxylic, aspartic, alkanesulfonic acids, such as methane and ethane sulfonic acids, arylosulfonic acids such as benzene- and paratoluene-sulfonic acids.
  • inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric or phosphoric acids
  • organic acids such as formic, acetic, trifluoroacetic, propionic, benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic
  • the salts are preferably those which allow easy crystallization.
  • the oxalic acid salt is particularly preferred.
  • the present invention provides a method for preparing the intermediate formula (I) under particularly attractive conditions, with an overall yield of the order of 70% and which therefore allows the failure encountered earlier to be overcome.
  • the compounds of formula (III), (IV) and (V) obtained using the method are novel and also constitute a subject matter of the invention, as novel industrial compounds and notably intermediate compounds required for preparing the compounds of formula (I).
  • the organic phase is isolated and washed with a solution of ammonium chloride (180 g) in water (0.6 l) and then with a solution of sodium chloride (200 g) in water (0.6 l).
  • the aqueous phases are extracted with ethyl acetate.
  • the combined organic phases are dried and then the product is precipitated by concentrating the solution under reduced pressure at 20° C. down to a volume of 0.4 l, and by then adding methyl-tert-butyl ether (0.25 l).
  • the suspension is cooled to ⁇ 10° C., stirred for 2 hours, filtered and then washed with an ethyl-acetate/methyl-tert-butyl ether mixture (7:3, 1 ⁇ 50 ml).
  • the crystals are dried at 40° C. under reduced pressure in order to obtain the expected ⁇ -keto-sulfoxonium (114.7 g, 279 mol, 89% yield).
  • Methanesulfonic acid (29.3 g, 0.305 mol) is slowly added to a mixture of ⁇ -keto-sulfoxonium (114 g, 0.277 mol) and of lithium chloride (13.3 g, 0.314 mol) in THF (1.71 ml) at room temperature.
  • the reaction mixture is heated to 50° C. for 5 hours and then cooled at room temperature.
  • Benzylhydroxylamine hydrochloride (46.4 g, 0.291 mol) and sodium acetate (29.6 g, 0.361 mol) are added.
  • the reaction mixture is diluted with ethyl acetate (0.5 l) and water (0.5 l and then stirred at room temperature for 18 hours.
  • the organic phase is isolated, concentrated down to a volume of 0.4 l and then washed with a sodium chloride solution (25 g) in water (0.25 l).
  • the aqueous phase is separated and then extracted with ethyl acetate (0.2 l).
  • the organic phases are combined and stirred for 1 hour with sodium sulfate (100 g).
  • the mixture is filtered and rinsed with ethyl acetate (2 ⁇ 0.1 l).
  • the ⁇ -chlorooxime solution is kept in the refrigerator for the next step where it will be used as such (130.8 g, 0.275 mol, 99.3% yield).
  • the ⁇ -chlorooxime solution (0.275 mol) is dried by azeotropic distillation down to a volume of 0.5 l and then diluted with ethyl acetate (0.5 l). The solution is cooled to 0° C. Methane sulfonic acid (136 g, 1.42 mol) is added within 15 minutes. The reaction mixture is heated to 40° C. for 1 hour and then cooled to room temperature before being added to a sodium bicarbonate solution (279 g, 3.40 mol) in water (1 l). The reaction mixture is heated to 50° C. for 3 hours and then cooled to room temperature. The organic phase is isolated and then washed with a sodium chloride solution (50 g) in water (0.5 l)).
  • the aqueous phases are extracted with ethyl acetate (0.5 l).
  • the organic phases are combined.
  • the solution is mixed with silica (100 g) and then for 20 minutes.
  • the solution is filtered and then washed with ethyl acetate.
  • the piperidine-oxime solution is concentrated down to a volume of 0.2 l and then kept in the refrigerator for the next step (88.8 g, 0.262 mol, 95.3% yield).
  • the E and Z isomers of the oximes are separated by chromatography and then analyzed by NMR;
  • the acetate, in which the piperidine-oxime obtained in stage B is in solution, is replaced with methanol by distillation and then diluted down to a volume of 0.2 L.
  • the piperidine-oxime solution (0.261 mol) is added within 30 minutes to an HCl solution (1.32 mol) in methanol (0.31 l) at 0° C.
  • Borane-pyridine (45.4 g, 0.49 mol) is added within 4 hours to the reaction mixture at 0° C.
  • the mixture is warmed up to room temperature and then stirred for one night.
  • the solution is concentrated down to a volume of 0.18 l and then diluted with dichloromethane (0.36 l) and water (0.36 l).
  • aqueous 50% soda solution is added up to a pH of 7.
  • the aqueous phase is separated and then extracted with dichloromethane (0.27 l).
  • the organic phase is washed with water.
  • the solution of (2S)-5-(benzyloxyamino)-piperidine-2-carboxylic acid benzyl ester is taken up and the dichloromethane is replaced with ethyl acetate by distillation and then dilution to a volume of 0.72 L.
  • An oxalic acid (23.78 g) solution in ethyl acetate (0.27 l) is added within 40 minutes.
  • the suspension is stirred for 2 hours at room temperature, filtered, washed with ethyl acetate (3 ⁇ 90 ml) and dried at 30° C. in order to obtain oxyamine oxalate as a powder (95.32 g, 0.221 mol, 85% yield).

Abstract

The disclosure relates to a method for preparing a compound of formula (I),
Figure US20130012712A1-20130110-C00001
wherein P1 and P2 are groups protecting the carboxylic acid and oxyamine functions, starting from pyroglutamic acid (S). The disclosure also relates to novel intermediates.

Description

  • The invention relates to a method for preparing a 2,5-disubstituted pyridine and novel intermediates.
  • PCT Application WO 02/10172 discloses novel azabicyclic compounds useful as drugs in the anti-bacterial field and their preparation using intermediate compounds of formula (A):
  • Figure US20130012712A1-20130110-C00002
  • wherein R′1, R′2, R3, Z and n are as defined in said application, and notably among these intermediate compounds, a piperidine of formula (A1):
  • Figure US20130012712A1-20130110-C00003
  • corresponding to a compound of formula (A) wherein n=1 and A′=CH2.
  • Among the compounds of formula (A1), the compound with the following formula (I) is of particular interest:
  • Figure US20130012712A1-20130110-C00004
  • wherein
  • P1 and P2 represent protecting groups of carboxylic acid and oxyamine functions, known to those skilled in the art, and notably those mentioned in PCT Application WO 02/10172.
  • The compound of formula (I) is in the form of a mixture of isomers (2S, 5R) and (2S, 5S).
  • The compound of formula (I) may be obtained as described in PCT Application WO 02/10172, notably in Example 32, starting from protected cis-5-hydroxy-piperidine-2-carboxylic acid.
  • The object of the present invention is a novel method for preparing the compound of formula (I), characterized in that the compound of formula (b):
  • Figure US20130012712A1-20130110-C00005
      • wherein P1 and P3 represent protecting groups of the carboxylic acid function and of the nitrogen,
        is treated by a HCl generating reagent, in order to obtain the compound of formula:
  • Figure US20130012712A1-20130110-C00006
      • wherein P1 and P3 are defined as here above,
        which is treated, without being isolated, with a hydroxylamine derivative, in order to obtain the compound of formula:
  • Figure US20130012712A1-20130110-C00007
  • wherein P1 and P3 are defined as here above and P2 represents a protecting group of the oxime, the amine of which is deprotected by the action of an acid, in order to obtain the compound of formula:
  • Figure US20130012712A1-20130110-C00008
      • wherein PI and P2 are as defined here above,
        which is cyclized by the action of a base in order to obtain the compound of formula:
  • Figure US20130012712A1-20130110-C00009
      • wherein P1 and P2 are defined as here above,
        the oxime function of which is reduced by the action of a reducing agent, in order to obtain the expected compound of formula (I) which, if desired, is put in the form of a salt by the action of an acid.
  • The beta-ketosulfoxonium compound of formula (b) may be obtained starting with the protected (S) pyrroglutamic acid of formula (a):
  • Figure US20130012712A1-20130110-C00010
      • wherein P1 and P3 are defined as here above,
        the ring of which is opened by the action of trimethylsulfoxonium iodide in the presence of sodium hydride in tetrahydrofurane.
  • The protecting group of the carboxylic acid function P1 is notably an alkyl, allyl, benzyl or p-nitrobenzyl ester residue; equivalent residues known to those skilled in the art may of course also be suitable.
  • P1 preferably is a benzyl group.
  • The protecting group of the nitrogen P3 notably forms a carbamate and preferably is a tert-butoxycarbonyl or benzyloxycarbonyl group, it may also be an electro-withdrawing group such as those known to one skilled in the art and referenced in <<Greene>> (Protective Groups in Organic Synthesis, 3rd edition).
  • P3 preferably is a tert-butoxycarbonyl group.
  • The protecting group of the hydroxylamine P2 is notably a benzyl or ally residue.
  • P2 preferably is a benzyl group.
  • The conditions generating HCl and allowing preparation of the compound of formula (II) preferably consist of using lithium chloride in the presence of a strong acid. Hydrochloric acid may also simply be used. The strong acid is for example hydrochloric acid, sulfuric acid, sulfonic acid such as methane sulfonic acid or ethane sulfonic acid.
  • According to a preferred condition of carrying out the invention, lithium chloride is used in the presence of methane sulfonic acid.
  • This is performed for example within an ether such as tetrahydrofurane or dioxane, within dimethylsulfoxide or within an ester such as ethyl acetate.
  • The protection of the ketone function of the compound of formula (II) is achieved without isolation of the intermediate, depending on the selected protective group, under conditions known to those skilled in the art.
  • Deprotection of the amine function is achieved by the action of an acid, for example hydrochloric acid, sulfonic acid, trifluoroacetic acid or an alkane sulfonic acid. Depending on the nature of the protective group, these conditions are known to one skilled in the art. Advantageous conditions consist of using a tert-butoxycarbonyl group and of cleaving it by the action of methane sulfonic acid. This may be performed for example in ethyl acetate.
  • The protected α-chlorooxime of formula (III) is preferably used without being isolated, i.e. in solution in the reaction solvent. The same applies for the protected α-chlorooxime of formula (IV).
  • The base used for cyclizing the compound of formula (IV) is for example an alkaline hydroxide, carbonate or bicarbonate, preferably sodium bicarbonate, or a base of the amine type, for example triethylamine.
  • The reducing agent used for reducing the oxime function is for example a reagent of the alkaline borohydride, diborane or borane-pyridine type in the presence of an acid, for example hydrochloric acid. This may be performed within an alcohol such as methanol or ethanol, or within another organic solvent such as dichloromethane.
  • The salification of the compound of formula (I) is, if necessary, achieved by adding to the compound an acid in a soluble phase.
  • Among the salts of the acids used for obtaining the products of formula (I), mention may be made, inter alia, to those formed with inorganic acids, such as hydrochloric, hydrobromic, hydroiodic, sulfuric or phosphoric acids, or with organic acids such as formic, acetic, trifluoroacetic, propionic, benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic, glyoxylic, aspartic, alkanesulfonic acids, such as methane and ethane sulfonic acids, arylosulfonic acids such as benzene- and paratoluene-sulfonic acids.
  • The salts are preferably those which allow easy crystallization. The oxalic acid salt is particularly preferred.
  • Compounds of the type (a) and (b) as well as of the type (II) the formulae of which are indicated above, are known, and mention may be made to the articles of J. Chem. Soc. Chem. Comm. 1993, p. 1434-1435 and Tet. Letters Vol. 29, No. 18, p. 2231-4 (1988).
  • Steps aimed at cyclizing the compounds (B) and (II) were tried.
  • Cyclization of compound (b) is possible but involves the use of a rhodium-based reagent. Application of this type of reagent on an industrial scale is not a very practical proposition and is very costly. Further, the yields obtained are not satisfactory. Alternatives to rhodium have been sought unsuccessfully.
  • Cyclization of compound (II) was however unable to be achieved, probably due to the reactivity of the carbonyl group.
  • The present invention provides a method for preparing the intermediate formula (I) under particularly attractive conditions, with an overall yield of the order of 70% and which therefore allows the failure encountered earlier to be overcome.
  • The compounds of formula (III), (IV) and (V) obtained using the method are novel and also constitute a subject matter of the invention, as novel industrial compounds and notably intermediate compounds required for preparing the compounds of formula (I).
  • The following example illustrates the invention.
    • EXAMPLE (2S)-5-benzyloxyamino-piperidine-2-carboxylic acid, benzylester and its oxalate Preparation (5S)-5-tert butyloxycarbonylamino-6-benzyl-oxy-2,6-dioxohexylidedi-methylsulfoxonium
  • Sodium hydride (60% in oil, 15 g, 0.375 mol) is added to a solution of trimethylsulfoxonium iodide in THF (0.4 l) under stirring at room temperature. The reaction mixture is diluted with DMSO (0.5 l) and is then cooled to −10° C. A solution of L-benzyl-N-Boc-glutamate (100 g, 0.313 mol) in THF (0.35 l) is added. The reaction mixture is warmed up to 0° C., stirred for 45 minutes and then added to a mixture of ammonium chloride (450 g), of water (1.5 l) and ethyl acetate (0.5 l) at 20° C. The organic phase is isolated and washed with a solution of ammonium chloride (180 g) in water (0.6 l) and then with a solution of sodium chloride (200 g) in water (0.6 l). The aqueous phases are extracted with ethyl acetate. The combined organic phases are dried and then the product is precipitated by concentrating the solution under reduced pressure at 20° C. down to a volume of 0.4 l, and by then adding methyl-tert-butyl ether (0.25 l). The suspension is cooled to −10° C., stirred for 2 hours, filtered and then washed with an ethyl-acetate/methyl-tert-butyl ether mixture (7:3, 1×50 ml). The crystals are dried at 40° C. under reduced pressure in order to obtain the expected β-keto-sulfoxonium (114.7 g, 279 mol, 89% yield).
  • NMR δ (400 MHz, MeOD) 1.49; (s, 9H, C4H9), 1.92; (m, 1H), 2.13; (m, 1H), 2.26; (m, 2H), 3.50; (s, 6H, S(CH3)2), 4.20; (m, 1H), 5.25; (m, 2H), 7.45; (m, 5H, C6H5).
    • Stage A (S)-5-(benzyloxyimino)-2-tert-butoxycarbonyl-amino-6-chloro-hexanoic acid benzyl ester (E+Z)
  • Methanesulfonic acid (29.3 g, 0.305 mol) is slowly added to a mixture of β-keto-sulfoxonium (114 g, 0.277 mol) and of lithium chloride (13.3 g, 0.314 mol) in THF (1.71 ml) at room temperature. The reaction mixture is heated to 50° C. for 5 hours and then cooled at room temperature. Benzylhydroxylamine hydrochloride (46.4 g, 0.291 mol) and sodium acetate (29.6 g, 0.361 mol) are added. The reaction mixture is diluted with ethyl acetate (0.5 l) and water (0.5 l and then stirred at room temperature for 18 hours. The organic phase is isolated, concentrated down to a volume of 0.4 l and then washed with a sodium chloride solution (25 g) in water (0.25 l). The aqueous phase is separated and then extracted with ethyl acetate (0.2 l). The organic phases are combined and stirred for 1 hour with sodium sulfate (100 g). The mixture is filtered and rinsed with ethyl acetate (2×0.1 l). The α-chlorooxime solution is kept in the refrigerator for the next step where it will be used as such (130.8 g, 0.275 mol, 99.3% yield).
  • NMR δ (400 MHz, CDCl3) 1.45; (s, 9H, C4H9), 1.96; (m, 1H, CH AHB), 2.16; (m, 1H, CHA H B), 2.47; (m, 2H, CH2), 4.06; and 4.20; (2s, 2H, CH2Ph), 4.38; (m, 1H), 5-5.4; (m, 4H), 7.35; (m, 10H, 2×C6H5); m/z (+ESI, LCMS) detected 475.0; [MH+],
    • Stage B (S)-5-(benzyloxyimino)-piperidine-2-carboxylic acid benzyl ester (E+Z)
  • The α-chlorooxime solution (0.275 mol) is dried by azeotropic distillation down to a volume of 0.5 l and then diluted with ethyl acetate (0.5 l). The solution is cooled to 0° C. Methane sulfonic acid (136 g, 1.42 mol) is added within 15 minutes. The reaction mixture is heated to 40° C. for 1 hour and then cooled to room temperature before being added to a sodium bicarbonate solution (279 g, 3.40 mol) in water (1 l). The reaction mixture is heated to 50° C. for 3 hours and then cooled to room temperature. The organic phase is isolated and then washed with a sodium chloride solution (50 g) in water (0.5 l)). The aqueous phases are extracted with ethyl acetate (0.5 l). The organic phases are combined. The solution is mixed with silica (100 g) and then for 20 minutes. The solution is filtered and then washed with ethyl acetate. The piperidine-oxime solution is concentrated down to a volume of 0.2 l and then kept in the refrigerator for the next step (88.8 g, 0.262 mol, 95.3% yield).
  • The E and Z isomers of the oximes are separated by chromatography and then analyzed by NMR;
  • NMR assumed isomer E δ (400 MHz, CDCl3) 1.8; (m, 1H), 2.25; (m, 1H), 3.15; (m, 1H), 3.35; (d, 1H), 3.62; (d, 1H), 3.64; (d, 1H), 5.1; (s, 2H, CH2Ph), 5.2; (s, 2H, CH2Ph), 7.37; (m, 10H, 2×C6H5);
  • NMR assumed isomer Z δ (400 MHz, CDCl3) 1.9; (m, 1H), 2.20-2.60; (m, 4H), 3.35; (d, 1H), 3.64; (d, 1H), 4.3; (d, 1H), 5.1; (s, 2H, CH2Ph), 5.2; (s, 2H, CH2Ph), 7.37; (m, 10H, 2×C6H5).
    • Stage C (2S)-5-(benzyloxyamino)-piperidine-2-carboxylic acid benzyl ester and its oxalate ((2S,5R) and (2S,5S) mixture ˜50/50).
  • The acetate, in which the piperidine-oxime obtained in stage B is in solution, is replaced with methanol by distillation and then diluted down to a volume of 0.2 L. The piperidine-oxime solution (0.261 mol) is added within 30 minutes to an HCl solution (1.32 mol) in methanol (0.31 l) at 0° C. Borane-pyridine (45.4 g, 0.49 mol) is added within 4 hours to the reaction mixture at 0° C. The mixture is warmed up to room temperature and then stirred for one night. The solution is concentrated down to a volume of 0.18 l and then diluted with dichloromethane (0.36 l) and water (0.36 l). An aqueous 50% soda solution is added up to a pH of 7. The aqueous phase is separated and then extracted with dichloromethane (0.27 l). The organic phase is washed with water. The solution of (2S)-5-(benzyloxyamino)-piperidine-2-carboxylic acid benzyl ester is taken up and the dichloromethane is replaced with ethyl acetate by distillation and then dilution to a volume of 0.72 L. An oxalic acid (23.78 g) solution in ethyl acetate (0.27 l) is added within 40 minutes. The suspension is stirred for 2 hours at room temperature, filtered, washed with ethyl acetate (3×90 ml) and dried at 30° C. in order to obtain oxyamine oxalate as a powder (95.32 g, 0.221 mol, 85% yield).

Claims (8)

1. A method for preparing the compound of formula (I)
Figure US20130012712A1-20130110-C00011
wherein P1 and P2 represent groups protecting the carboxylic acid and oxyamine functions, comprising a beta-ketosulfoxonium compound of formula:
Figure US20130012712A1-20130110-C00012
wherein P1 is as defined here above and P3 represents an amine protecting group, is treated with a reagent generating HCl, in order to obtain the compound of formula:
Figure US20130012712A1-20130110-C00013
wherein P1 and P2 are as defined here above, which is treated without isolating it, with hydroxylamine derivative, in order to obtain the compound of formula:
Figure US20130012712A1-20130110-C00014
wherein P1 and P3 are as defined here above and P2 represents a protecting group of the oxime, the amine of which is de-protected by the action of an acid, in order to obtain the compound of formula:
Figure US20130012712A1-20130110-C00015
wherein P1 and P2 are defined as here above, which is cyclized by the action of a base, in order to obtain the compound of formula:
Figure US20130012712A1-20130110-C00016
wherein P1 and P2 are defined as here above, the oxime function of which is reduced by the action of a reducing agent, in order to obtain the expected compound of formula (I) which, if desired, is salified by the action of an acid.
2. The method according to claim 1, wherein P1 represents a benzyl group.
3. The method according to claim 1, wherein P3 represents a tert-butoxy-carbonyl group.
4. The method according to claim 1, wherein P2 represents a benzyl group.
5. The method according to claim 1, wherein the compound of formula (b) is treated with lithium chloride in the presence of methane sulfonic acid.
6. The method according to claim 1, wherein the amine of the compound of formula (III) is de-protected by the action of methane sulfonic acid, without prior isolation of this compound.
7. The method according to claim 1, wherein the cyclization of the compound of formula (IV) is carried out by the action of sodium bicarbonate.
8-10. (canceled)
US13/616,995 2007-09-14 2012-09-14 Method for preparing disubstituted piperidine and intermediates Abandoned US20130012712A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/616,995 US20130012712A1 (en) 2007-09-14 2012-09-14 Method for preparing disubstituted piperidine and intermediates

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0706449A FR2921060B1 (en) 2007-09-14 2007-09-14 NOVEL PROCESS FOR PREPARING DISUBSIDED PIPERIDINE AND NOVEL INTERMEDIATES
FR0706449 2007-09-14
PCT/FR2008/001280 WO2009090320A1 (en) 2007-09-14 2008-09-12 Method for preparing disubstituted piperidine and intermediates
US67774110A 2010-03-11 2010-03-11
US13/616,995 US20130012712A1 (en) 2007-09-14 2012-09-14 Method for preparing disubstituted piperidine and intermediates

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/FR2008/001280 Division WO2009090320A1 (en) 2007-09-14 2008-09-12 Method for preparing disubstituted piperidine and intermediates
US67774110A Division 2007-09-14 2010-03-11

Publications (1)

Publication Number Publication Date
US20130012712A1 true US20130012712A1 (en) 2013-01-10

Family

ID=39428023

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/677,741 Active 2029-04-20 US8288553B2 (en) 2007-09-14 2008-09-12 Method for preparing disubstituted piperidine and intermediates
US13/616,995 Abandoned US20130012712A1 (en) 2007-09-14 2012-09-14 Method for preparing disubstituted piperidine and intermediates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/677,741 Active 2029-04-20 US8288553B2 (en) 2007-09-14 2008-09-12 Method for preparing disubstituted piperidine and intermediates

Country Status (10)

Country Link
US (2) US8288553B2 (en)
EP (1) EP2200983B1 (en)
JP (1) JP5421265B2 (en)
CN (1) CN102056901B (en)
AT (1) ATE539057T1 (en)
CA (1) CA2699438C (en)
ES (1) ES2380098T3 (en)
FR (1) FR2921060B1 (en)
HK (1) HK1145324A1 (en)
WO (1) WO2009090320A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8927724B2 (en) 2012-03-30 2015-01-06 Cubist Pharmaceuticals, Inc. Isoxazole beta-lactamase inhibitors
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9096523B2 (en) 2011-03-31 2015-08-04 Kaneka Corporation Process for preparing cyclic amine compounds
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
US9181250B2 (en) 2012-05-30 2015-11-10 Meiji Seika Pharma Co., Ltd. Beta-lactamase inhibitor and process for preparing the same
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US9676777B2 (en) 2010-12-22 2017-06-13 Meiji Seika Pharma Co., Ltd. Compounds useful for producing an optically active diazabicyclooctane compound
WO2017136254A1 (en) * 2016-02-04 2017-08-10 Merck Sharp & Dohme Corp. Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
US10000492B2 (en) 2013-09-24 2018-06-19 Meiji Seika Pharma Co., Ltd. Process for producing diazabicyclooctane derivative
US10131665B2 (en) 2013-10-08 2018-11-20 Meiji Seika Pharma Co., Ltd. Processes for producing diazabicyclooctane compounds
US10294224B2 (en) 2014-12-05 2019-05-21 Meiji Seika Pharma Co., Ltd. Lyophilized composition of a diazabicyclooctane compound and process of producing the same
WO2019127903A1 (en) 2017-12-25 2019-07-04 新发药业有限公司 Simple preparation method for avibactam
WO2019127902A1 (en) 2017-12-28 2019-07-04 新发药业有限公司 Method for preparing 5r-benzyloxyaminopiperidin-2s-carboxylic acid or derivative thereof
WO2020219405A1 (en) * 2019-04-26 2020-10-29 Merck Sharp & Dohme Corp. Process for the preparation of intermediates useful for making (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2951171A1 (en) 2009-10-09 2011-04-15 Novexel NOVEL SODIUM SALT OF A CRYSTALLIZED ENANTIOMER AZABICYCLIC COMPOUND AND NOVEL POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS AND THEIR PREPARATION
CA2822758C (en) * 2010-12-22 2018-03-20 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivative and process for preparing the same
US8829191B2 (en) 2011-06-17 2014-09-09 Melanie Simone Ronsheim Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
UA111925C2 (en) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
NZ711343A (en) 2013-03-08 2016-07-29 Wockhardt Ltd Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
CN107540601B (en) * 2016-06-28 2019-07-19 新发药业有限公司 The convenient preparation method of 5R- benzyloxy amino piperidine -2S- formic acid esters and its oxalates
CN107540600B (en) * 2016-06-28 2019-07-09 新发药业有限公司 A kind of recoverying and utilizing method of AVM hereinafter Batan intermediate production waste liquid
CN106699756B (en) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 The synthetic method of beta lactamase restrainer AVM hereinafter Batan
CN109400521B (en) * 2017-08-18 2020-05-08 新发药业有限公司 Improved preparation method of 5R-benzyloxyaminopiperidine-2S-formate and oxalate thereof
CN110498762B (en) * 2019-08-28 2020-10-27 山东安信制药有限公司 Synthesis method of (2S,5R) -5- [ (benzyloxy) amino ] -piperidine-2-ethyl formate
CN114989169A (en) * 2022-07-04 2022-09-02 哈药集团技术中心 Preparation method of avibactam sodium

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5059377A (en) * 1973-10-04 1975-05-22
JPS63162666A (en) * 1986-12-26 1988-07-06 Asahi Chem Ind Co Ltd Aminooxyacetic acid derivative and production thereof
JPH0393762A (en) * 1989-09-04 1991-04-18 Wako Pure Chem Ind Ltd Production of 4-halogeno-2-alkoxyimino-3-oxofatty acid
FR2812635B1 (en) * 2000-08-01 2002-10-11 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION AND USE AS MEDICAMENTS IN PARTICULAR AS ANTI-BACTERIALS
US6399793B1 (en) * 2000-08-16 2002-06-04 Bristol-Myers Squibb Company Process for the preparation of α' chloroketones
FR2825705B1 (en) * 2001-06-08 2005-05-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-BACTERIANS
FR2833596B1 (en) * 2001-12-14 2005-02-18 Aventis Pharma Sa PROCESS FOR THE PREPARATION OF ECHINOCANDIN DERIVATIVES
FR2835186B1 (en) * 2002-01-28 2006-10-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
FR2848210B1 (en) * 2002-12-06 2007-10-19 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-BACTERIALS AND INHIBITORS OF BETA-LACTAMASES
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
JP3935126B2 (en) * 2003-09-24 2007-06-20 雅裕 亀田 Decorative lamp
US7396934B2 (en) * 2003-11-17 2008-07-08 Youssef El-Ahmad Process for preparing 3-fluoroquinolines
JP2007126358A (en) * 2004-01-20 2007-05-24 Fujiyakuhin Co Ltd Phenylalanine derivative

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9676777B2 (en) 2010-12-22 2017-06-13 Meiji Seika Pharma Co., Ltd. Compounds useful for producing an optically active diazabicyclooctane compound
US9096523B2 (en) 2011-03-31 2015-08-04 Kaneka Corporation Process for preparing cyclic amine compounds
US8877743B2 (en) 2011-12-02 2014-11-04 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US10544146B2 (en) 2011-12-02 2020-01-28 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US10030019B2 (en) 2011-12-02 2018-07-24 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US9393239B2 (en) 2011-12-02 2016-07-19 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and betalactamase inhibitors
US8962844B2 (en) 2012-03-30 2015-02-24 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8962843B2 (en) 2012-03-30 2015-02-24 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8927724B2 (en) 2012-03-30 2015-01-06 Cubist Pharmaceuticals, Inc. Isoxazole beta-lactamase inhibitors
US8933233B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8940897B2 (en) 2012-03-30 2015-01-27 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
US9181250B2 (en) 2012-05-30 2015-11-10 Meiji Seika Pharma Co., Ltd. Beta-lactamase inhibitor and process for preparing the same
US9708320B2 (en) 2012-05-30 2017-07-18 Meiji Seika Pharma Co., Ltd. β-lactamase inhibitor and process for preparing the same
US11731971B2 (en) 2012-05-30 2023-08-22 Meiji Seika Pharma Co., Ltd. Processes for preparing a diazabicyclooctane compound
US10556905B2 (en) 2012-05-30 2020-02-11 Meiji Seika Pharma Co., Ltd. Processes for preparing a diazabicyclooctane compound
US11117896B2 (en) 2012-05-30 2021-09-14 Meiji Seika Pharma Co., Ltd. Processes for preparing a diazabicyclooctane compound
US10023573B2 (en) 2012-05-30 2018-07-17 Meiji Seika Pharma Co., Ltd. Beta-lactamase inhibitor and process for preparing the same
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
US10000492B2 (en) 2013-09-24 2018-06-19 Meiji Seika Pharma Co., Ltd. Process for producing diazabicyclooctane derivative
US10000491B2 (en) 2013-09-24 2018-06-19 Meiji Seika Pharma Co., Ltd. Process for producing diazabicyclooctane derivative and intermediate thereof
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
US10604522B2 (en) 2013-10-08 2020-03-31 Meiji Seika Pharma Co., Ltd. Processes for producing diazabicyclooctane compounds
US10131665B2 (en) 2013-10-08 2018-11-20 Meiji Seika Pharma Co., Ltd. Processes for producing diazabicyclooctane compounds
US11414417B2 (en) 2013-10-08 2022-08-16 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivative and production process thereof
US11117895B2 (en) 2014-12-05 2021-09-14 Meiji Seika Pharma Co., Ltd. Process for producing crystals of a diazabicyclooctane derivative
US10294224B2 (en) 2014-12-05 2019-05-21 Meiji Seika Pharma Co., Ltd. Lyophilized composition of a diazabicyclooctane compound and process of producing the same
WO2017136254A1 (en) * 2016-02-04 2017-08-10 Merck Sharp & Dohme Corp. Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
US10472345B2 (en) 2016-02-04 2019-11-12 Merck Sharp & Dohme Corp. Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
WO2019127903A1 (en) 2017-12-25 2019-07-04 新发药业有限公司 Simple preparation method for avibactam
WO2019127902A1 (en) 2017-12-28 2019-07-04 新发药业有限公司 Method for preparing 5r-benzyloxyaminopiperidin-2s-carboxylic acid or derivative thereof
WO2020219405A1 (en) * 2019-04-26 2020-10-29 Merck Sharp & Dohme Corp. Process for the preparation of intermediates useful for making (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
CN114206851A (en) * 2019-04-26 2022-03-18 默沙东公司 Process for the preparation of intermediates useful in the preparation of (2S,5R) -7-oxo-N-piperidin-4-yl-6- (sulfate) -1, 6-diazabicyclo [3.2.1] octane-2-carboxamide

Also Published As

Publication number Publication date
CA2699438A1 (en) 2009-07-23
US20100197928A1 (en) 2010-08-05
WO2009090320A1 (en) 2009-07-23
JP5421265B2 (en) 2014-02-19
US8288553B2 (en) 2012-10-16
FR2921060B1 (en) 2012-06-15
JP2010539147A (en) 2010-12-16
ES2380098T3 (en) 2012-05-08
HK1145324A1 (en) 2011-04-15
CN102056901B (en) 2014-09-03
EP2200983B1 (en) 2011-12-28
FR2921060A1 (en) 2009-03-20
ATE539057T1 (en) 2012-01-15
CN102056901A (en) 2011-05-11
EP2200983A1 (en) 2010-06-30
CA2699438C (en) 2016-11-22

Similar Documents

Publication Publication Date Title
US8288553B2 (en) Method for preparing disubstituted piperidine and intermediates
US20090176986A1 (en) Process for the Preparation of Pyridine Heterocycle Cgrp Antagonist Intermediate
KR20170029506A (en) Process for the preparation of 4-alkoxy-3-hydroxypicolinic acids
JP4560293B2 (en) Method for producing pharmaceutically effective compound (granisetron)
US8420846B2 (en) Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates
JP5585822B2 (en) Method for producing optically active nipecotic acid derivative
US10501403B2 (en) Method for preparation of (S)-N1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrochloride
US20100029939A1 (en) Preparation of ketone amides
US6562975B1 (en) Process for preparing zolpidem
US11401269B2 (en) Intermediates and processes for the preparation of Linagliptin and its salts
CZ257593A3 (en) Derivatives of phenylacetic acid esters and process for preparing thereof
US6177564B1 (en) Process for the synthesis of N-benzyl-3-(4-fluorophenyl)-1-4-oxazin-2-one
US6603025B1 (en) Method of production of benzofuranone oximes
WO2019008595A1 (en) Process for the preparation of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1- methylpiperidin-4-yl)urea and salts thereof
US20040116711A1 (en) Process for producing 5-substituted oxazole compounds and 5-substituted imidazole compounds
EP4153599B1 (en) Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
US20120259116A1 (en) Novel Process for the Preparation of Paliperidone
KR101114893B1 (en) - Process for preparing pyridine-substituted amino ketal derivatives
US20220033356A1 (en) Process for the preparation of pharmaceutical agent
US20050176752A1 (en) Process for the preparation of piperidine derivatives
US20110230660A1 (en) Method for preparing a spiroindoline and a precursor thereof
JP2001247549A (en) Method of producing 1-position substituted hydantoins
WO2015150887A1 (en) Process for the preparation of anagliptin or its salts
JP2003026672A (en) New method of production for 3-aminooxetan and intermediate
EP0650957A1 (en) Aniline derivative and process for producing the same

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION